Meiji Seika Pharma will present 10 studies on Nacubactam at ESCMID Global 2026 including Phase III Integral-2 results in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results